190,044 Shares in CVS Health Corporation $CVS Bought by Wealthfront Advisers LLC

Key Points

• Wealthfront Advisers bought 190,044 CVS Health shares worth approximately $19.66 million during the second quarter. Institutional investors collectively own 80.66% of CVS’s outstanding stock.
• CVS reported stronger-than-expected quarterly results, with EPS of $2.58 versus the $1.87 consensus estimate and revenue of $106.1 billion. The company raised its 2026 adjusted operating-income outlook, supporting optimism about its turnaround.
• Analyst sentiment remains favorable, with 22 Buy ratings and two Holds, an overall “Moderate Buy” rating, and a consensus price target of $106.75. CVS also maintains a quarterly dividend of $0.665 per share, representing a 2.8% annualized yield.

Wealthfront Advisers LLC purchased a new position in shares of CVS Health Corporation (NYSE:CVS - Free Report) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 190,044 shares of the pharmacy operator's stock, valued at approximately $19,660,000.

Several other hedge funds and other institutional investors have also made changes to their positions in CVS. Caitong International Asset Management Co. Ltd increased its stake in shares of CVS Health by 407.2% during the third quarter. Caitong International Asset Management Co. Ltd now owns 350 shares of the pharmacy operator's stock worth $26,000 after buying an additional 281 shares during the period. Swiss RE Ltd. purchased a new position in CVS Health in the fourth quarter worth approximately $26,000. Sankala Group LLC acquired a new position in CVS Health during the 4th quarter worth approximately $28,000. Global Trust Asset Management LLC increased its position in shares of CVS Health by 344.8% in the 1st quarter. Global Trust Asset Management LLC now owns 387 shares of the pharmacy operator's stock valued at $28,000 after purchasing an additional 300 shares during the last quarter. Finally, Mcguire Capital Advisors Inc. acquired a new stake in shares of CVS Health in the 4th quarter valued at $28,000. Hedge funds and other institutional investors own 80.66% of the company's stock.

Key Stories Impacting CVS Health

Here are the key news stories impacting CVS Health this week:

• Positive Sentiment: CVS reported strong second-quarter results, with earnings per share rising more than 40% year over year as profitability in its Health Care Benefits segment improved. The company also raised its 2026 adjusted operating income outlook, reinforcing the recovery story. CVS Q2 EPS Gains From Improved Health Care Benefits Profitability
• Positive Sentiment: CVS appointed Teresa Heitsenrether, JPMorgan’s data and analytics chief, to its board. Her technology, analytics and operating experience could support CVS’s artificial-intelligence and data initiatives, potentially improving efficiency and decision-making across its businesses. CVS adds JPMorgan data executive to board amid AI push
• Positive Sentiment: Brokerages assigned CVS an average “Moderate Buy” rating, reflecting improved earnings momentum and optimism about Aetna’s performance. CVS Health Given Average Rating of Moderate Buy

Insider Buying and Selling

In other CVS Health news, Director Larry Robbins sold 370,462 shares of CVS Health stock in a transaction that occurred on Thursday, May 21st. The stock was sold at an average price of $93.45, for a total transaction of $34,619,673.90. Following the transaction, the director owned 4,824,799 shares of the company's stock, valued at $450,877,466.55. The trade was a 7.13% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. 0.85% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

CVS has been the subject of a number of analyst reports. Morgan Stanley boosted their target price on shares of CVS Health from $106.00 to $111.00 and gave the stock an "overweight" rating in a research note on Thursday, June 4th. Robert W. Baird set a $107.00 price target on CVS Health in a report on Thursday, August 6th. DA Davidson increased their price objective on CVS Health from $80.00 to $100.00 and gave the company a "buy" rating in a report on Thursday, May 7th. Barclays raised their target price on CVS Health from $106.00 to $108.00 and gave the stock an "overweight" rating in a research report on Thursday, August 6th. Finally, HSBC restated a "hold" rating and set a $103.00 target price on shares of CVS Health in a research note on Monday, July 6th. Twenty-two investment analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company's stock. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $106.75.

CVS Health Price Performance

Shares of CVS opened at $94.87 on Wednesday. The company has a debt-to-equity ratio of 0.74, a current ratio of 0.87 and a quick ratio of 0.66. CVS Health Corporation has a 1-year low of $69.51 and a 1-year high of $110.68. The stock has a market cap of $121.33 billion, a PE ratio of 25.10, a price-to-earnings-growth ratio of 0.93 and a beta of 0.61. The firm has a fifty day moving average price of $102.41 and a 200 day moving average price of $88.56.

CVS Health (NYSE:CVS - Get Free Report) last issued its quarterly earnings data on Wednesday, August 5th. The pharmacy operator reported $2.58 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.87 by $0.71. CVS Health had a return on equity of 13.12% and a net margin of 1.18%.The company had revenue of $106.10 billion for the quarter, compared to analyst estimates of $100.03 billion. During the same quarter last year, the company posted $1.81 earnings per share. The business's quarterly revenue was up 7.3% compared to the same quarter last year. CVS Health has set its FY 2026 guidance at 7.900-8.100 EPS. As a group, sell-side analysts anticipate that CVS Health Corporation will post 8.02 EPS for the current year.

CVS Health Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Monday, August 3rd. Investors of record on Thursday, July 23rd were paid a dividend of $0.665 per share. This represents a $2.66 dividend on an annualized basis and a yield of 2.8%. The ex-dividend date was Thursday, July 23rd. CVS Health's dividend payout ratio (DPR) is currently 70.37%.

CVS Health Profile

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source